Table 1.
Operational definitions and treatment protocols used in MSF Clinic.
Table 2.
Baseline characteristics of presumptive second line ART failure cases referred to a Médecins Sans Frontières clinic in Mumbai, India, January 2011-September 2017 (n = 120).
Fig 1.
Patient flow, retention in care and viral suppression at 6 and 12 months among presumptive second line ART failure cases referred to a MSF clinic in Mumbai, India, January 2011-June 2016.
* 1 SL Cohort patient were not tested at 6 months. ** 2 SL cohort patient were not tested at 12 month. SL- Second Line, LFU- Lost to Follow Up, TO- Transfer Out, EAC- Enhanced Adherence Counselling, VL- Viral Load.
Table 3.
Drug resistance mutation patterns among second line ART failure cases referred to a MSF clinic in Mumbai, India, January 2011-September 2017.
Table 4.
Major mutations on participants tested for drug resistance ART cases in the MSF clinic between January 2011 and September 2017.
Fig 2.
Resistance patterns in presence and absence of previous exposure to specific ARV drugs among second line ART failure cases referred to a MSF clinic in Mumbai, India, January 2011-September 2017.
TDF- Tenofovir, AZT- Zidovudine, ABC-Abacavir, D4T- Stavudine, EFV (Efavirenz), NVP -Nevirapine, LPV- Lopinavir, ATV- Atazanavir, DRV-Darunavir, RAL- Raltegravir, EVG- Elvitegravir, DTG- Dolutegravir.